6204-41-7

Usage

Uses

Used in Pharmaceutical Synthesis:
(E)-4-[(benzyloxy)methyl]-2-(bromomethyl)-1,3-dioxolane is used as a reagent for the introduction of benzyloxy and bromomethyl functional groups into organic molecules, which is crucial for the synthesis of various pharmaceuticals. Its ability to provide these functional groups makes it a valuable component in the development of new drugs and medicines.
Used in Organic Synthesis:
In the field of organic synthesis, (E)-4-[(benzyloxy)methyl]-2-(bromomethyl)-1,3-dioxolane is used as a building block for the creation of complex organic compounds. Its unique structure allows for the formation of a variety of molecules, contributing to the advancement of chemical research and the development of new materials.
Used in Chemical Process Development:
(E)-4-[(benzyloxy)methyl]-2-(bromomethyl)-1,3-dioxolane also serves as a starting material in the development of new chemical processes. Its potential in this area lies in its ability to be modified and incorporated into various molecular structures, leading to the discovery of innovative processes and materials.

InChI:InChI=1/C12H15BrO3/c13-6-12-15-9-11(16-12)8-14-7-10-4-2-1-3-5-10/h1-5,11-12H,6-9H2/t11-,12-/m1/s1

Upstream product

• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 13071-59-5 3-benzyloxypropan-1,2-diol 
• 21668-09-7 sulpho-salicylic acid 
• 56552-80-8 (R)-3-benzyloxy-1,2-propanediol 

Downstream Products

• 87179-37-1 (+/-)-2-(bromomethyl)-4-(hydroxymethyl)-1,3-dioxalane 

Relevant academic research and scientific papers

2-Hydroxymethyl-1,4-dioxane: Synthesis, resolution and determination of the absolute configurations of the enantiomers

2-Hydroxymethyl-1, 4-dioxane 3 was resolved via salt formation between its hydrogen phthalate and (R)- or (S)-1-phenylethylamine, selective crystallization of the resultant diastereomeric mixtures and subsequent recovery of its enantiomers by saponification. The progress of the resolution was followed by chiral HPLC and the absolute stereochemistry of the two enantiomers determined by comparison of their specific rotations with that of (R)-3 synthesized from enantiomerically pure (R)-1-O-benzylglycerol. The results of the synthesis of 3 and of its resolution are discussed and compared with those previously obtained for 1,2-isopropylidene glycerol evaluating the consequences of replacement of ispropylidene with an ethylene bridge.

Syntheses of All Four Stereoisomers Which Are Conformationally Constrained 1,4-Dioxanyl Analogs of the Antineoplastic Ether Lipid ET-18-OCH3

The syntheses of each of the four nearly optically pure stereoisomers of oxy>phosphocholine (2,3,2',3') were performed by two parallel divergent sequences.Phosphocholines 2 and 3 were prepared via the corresponding 5-heptadecyl-2-(hydroxymethyl)-1,4-dioxanes 21 and 23, respectively, from the completely regiospecific mixed-hydride reductions of (1R,4S,5S)-4-heptadecyl-3,6,8-trioxabicyclooctane (19) and (1R,4R,5S)-4-heptadecyl-3,6,8-trioxabicyclooctane (20), respectively.The two 4-heptadecyl-3,6,8-trioxabicyclooctanes 19 and 20 were the two separable products from an intramolecular cyclization reaction.By a parallel divergent sequence from the enantiomeric starting material, 3-O-benzyl-sn-glycerol (16'), the other two diastereomeric oxy>phosphocholines 2' and 3' were prepared.These four monocyclic oxy>phosphocholines (2,3,2',3') are conformationally constrained analogs of the antineoplastic and immunomodulatory ether lipid rac-2-O-methyl-1-O-octadecylglycero-3-phosphocholine (rac-1) (rac-ET-18-OCH3, rac-Edelfosine).

Halogenated derivatives of 1,3-dioxolane having mucolytic activity

Compounds useful as expectorants and fluidizers of tracheobronchial mucus having the specified formula are disclosed, the compounds having at least one bromine or iodine atom as a substituent. A process for preparing such compounds is also disclosed.